Summary | |
---|---|
Symbol | NT5E |
Name | 5'-nucleotidase, ecto (CD73) |
Aliases | CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73 |
Chromosomal Location | 6q14-q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane; Lipid-anchor, GPI-anchor. |
Domain |
PF02872 5'-nucleotidase PF00149 Calcineurin-like phosphoesterase |
Function |
Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities. |
Biological Process |
GO:0006152 purine nucleoside catabolic process GO:0006195 purine nucleotide catabolic process GO:0006196 AMP catabolic process GO:0006213 pyrimidine nucleoside metabolic process GO:0007159 leukocyte cell-cell adhesion GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009123 nucleoside monophosphate metabolic process GO:0009125 nucleoside monophosphate catabolic process GO:0009126 purine nucleoside monophosphate metabolic process GO:0009128 purine nucleoside monophosphate catabolic process GO:0009150 purine ribonucleotide metabolic process GO:0009154 purine ribonucleotide catabolic process GO:0009158 ribonucleoside monophosphate catabolic process GO:0009161 ribonucleoside monophosphate metabolic process GO:0009163 nucleoside biosynthetic process GO:0009164 nucleoside catabolic process GO:0009166 nucleotide catabolic process GO:0009167 purine ribonucleoside monophosphate metabolic process GO:0009169 purine ribonucleoside monophosphate catabolic process GO:0009261 ribonucleotide catabolic process GO:0016311 dephosphorylation GO:0019439 aromatic compound catabolic process GO:0031348 negative regulation of defense response GO:0032102 negative regulation of response to external stimulus GO:0034655 nucleobase-containing compound catabolic process GO:0042278 purine nucleoside metabolic process GO:0042451 purine nucleoside biosynthetic process GO:0042454 ribonucleoside catabolic process GO:0042455 ribonucleoside biosynthetic process GO:0044270 cellular nitrogen compound catabolic process GO:0046033 AMP metabolic process GO:0046085 adenosine metabolic process GO:0046086 adenosine biosynthetic process GO:0046128 purine ribonucleoside metabolic process GO:0046129 purine ribonucleoside biosynthetic process GO:0046130 purine ribonucleoside catabolic process GO:0046135 pyrimidine nucleoside catabolic process GO:0046434 organophosphate catabolic process GO:0046700 heterocycle catabolic process GO:0050727 regulation of inflammatory response GO:0050728 negative regulation of inflammatory response GO:0072522 purine-containing compound biosynthetic process GO:0072523 purine-containing compound catabolic process GO:0072527 pyrimidine-containing compound metabolic process GO:0072529 pyrimidine-containing compound catabolic process GO:1901136 carbohydrate derivative catabolic process GO:1901292 nucleoside phosphate catabolic process GO:1901361 organic cyclic compound catabolic process GO:1901565 organonitrogen compound catabolic process GO:1901657 glycosyl compound metabolic process GO:1901658 glycosyl compound catabolic process GO:1901659 glycosyl compound biosynthetic process |
Molecular Function |
GO:0008252 nucleotidase activity GO:0008253 5'-nucleotidase activity GO:0016791 phosphatase activity GO:0042578 phosphoric ester hydrolase activity |
Cellular Component |
GO:0031225 anchored component of membrane |
KEGG |
hsa00230 Purine metabolism hsa00240 Pyrimidine metabolism hsa00760 Nicotinate and nicotinamide metabolism hsa01100 Metabolic pathways |
Reactome |
R-HSA-1430728: Metabolism R-HSA-15869: Metabolism of nucleotides R-HSA-196854: Metabolism of vitamins and cofactors R-HSA-196849: Metabolism of water-soluble vitamins and cofactors R-HSA-196807: Nicotinate metabolism R-HSA-74259: Purine catabolism R-HSA-73847: Purine metabolism R-HSA-73621: Pyrimidine catabolism R-HSA-73848: Pyrimidine metabolism |
Summary | |
---|---|
Symbol | NT5E |
Name | 5'-nucleotidase, ecto (CD73) |
Aliases | CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73 |
Chromosomal Location | 6q14-q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between NT5E and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between NT5E and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | NT5E |
Name | 5'-nucleotidase, ecto (CD73) |
Aliases | CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73 |
Chromosomal Location | 6q14-q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of NT5E in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | NT5E |
Name | 5'-nucleotidase, ecto (CD73) |
Aliases | CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73 |
Chromosomal Location | 6q14-q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of NT5E in various data sets.
|
Points in the above scatter plot represent the mutation difference of NT5E in various data sets.
|
Summary | |
---|---|
Symbol | NT5E |
Name | 5'-nucleotidase, ecto (CD73) |
Aliases | CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73 |
Chromosomal Location | 6q14-q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NT5E. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | NT5E |
Name | 5'-nucleotidase, ecto (CD73) |
Aliases | CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73 |
Chromosomal Location | 6q14-q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NT5E. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NT5E. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | NT5E |
Name | 5'-nucleotidase, ecto (CD73) |
Aliases | CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73 |
Chromosomal Location | 6q14-q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NT5E. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | NT5E |
Name | 5'-nucleotidase, ecto (CD73) |
Aliases | CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73 |
Chromosomal Location | 6q14-q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of NT5E expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | NT5E |
Name | 5'-nucleotidase, ecto (CD73) |
Aliases | CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73 |
Chromosomal Location | 6q14-q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between NT5E and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | NT5E |
Name | 5'-nucleotidase, ecto (CD73) |
Aliases | CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73 |
Chromosomal Location | 6q14-q21 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting NT5E collected from DrugBank database. |
Details on drugs targeting NT5E.
|